Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler

International Journal of Neuropsychopharmacology

Volumn 14, Issue 3, 2011, Pages 389-398

  Esterlis, Irina ^a   Mitsis, Effie M ^c   Batis, Jeffery C ^b   Bois, Frederic ^a   Picciotto, Marina R ^a   Stiklus, Stephanie M ^a   Kloczynski, Tracy ^a   Perry, Edward ^a   Seibyl, John P ^b   McKee, Sherry ^a   Staley, Julie K ^a   Cosgrove, Kelly P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

2* nAChR occupancy; nicotine; nicotine inhaler; SPECT brain imaging

Indexed keywords

NICOTINE; NICOTINIC RECEPTOR BETA2;

ADULT; ARTICLE; BRAIN CORTEX; CEREBELLUM; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING CESSATION; THALAMUS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADMINISTRATION, INHALATION; ADULT; BEHAVIOR, ADDICTIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; RECEPTORS, NICOTINIC; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 79960351147     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710001227     Document Type: Article

References (48)

1. ACS (2009). Smoking Cessation Aids Use Increases, Success Rate Declines. American Cancer Society (http://www.cancer.org/index).
2. Benowitz N (1999). Nicotine addiction. Primary Care 26, 611-631 (Pubitemid 29441999)
3. Benowitz N, Jacob P (1997). Individual differences in nicotine kinetics and metabolism in humans. NIDA Research Monographs 173, 48-64
4. Bergstrom M, Nordberg A, Lunell E, Aton G, et al. (1995). Regional disposition of inhaled 11C-vapor in the human airways as visualized by positron emission tomography. Clinical Pharmacological Therapy 57, 309-317
5. Brody A, Mandelkern M, Costello M, Abrams A, et al. (2009). Brain nicotinic cetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. International Journal of Neuropsychopharmacology 12, 305-316
6. Brody A, Mandelkern M, London E, Olmstead R, et al. (2006). Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Archives of General Psychiatry 63, 907-915 (Pubitemid 44192334)
7. Caldwell B, Dickson S, Burgess C, Siebers R, et al. (2009). A pilot study of nicotine delivery to smokers from a metered-dose inhaler. Nicotine and Tobacco Research 11, 342-347
8. Cunningham V, Rabiner E, Slifstein M, Laruelle M, Gunn RN (2010). Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. Journal of Cerebral Blood Flow and Metabolism 30, 46-50
9. Endres C, Carson R (1998). Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands. Journal of Cerebral Blood Flow and Metabolism 18, 1196-1210 (Pubitemid 28509834)
10. Epping-Jordan M, Picciotto M, Changeux J, Pich EM (1999). Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice. Psychopharmacology 147, 25-26 (Pubitemid 30010017)
11. Esterlis I, Cosgrove K, et al. (2010). Quantification of smoking induced occupancy of b2-nicotinic acetylcholine receptors: estimation of nondisplaceable binding. Journal of Nuclear Medicine 51, 1226-1233
12. Fujita M, Tamagnan G, Zoghbi SS, Al-Tikriti MS, et al. (2010). Measurement of alpha4beta2 nicotinic acetylcholine receptors with [123I]5-I-A-85380 SPECT. Journal of Nuclear Medicine 41, 1552-1560
13. Gourlay S, Benowitz N (1997). Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray and intravenous nicotine. Clinical Pharmacological Therapy 62, 453-463 (Pubitemid 27475230)
14. Hariharan M, VanNoord T, Greden JF (1988). A highperformance liquid-chromatographic method for routine simultaneous determination of nicotine and cotinine in plasma. Clinical Chemistry 34, 724-729
15. Hatsukami D, Hughes J, Pickens R, SvikisD(1984). Tobacco withdrawal symptoms: An experimental analysis. Psychopharmacology 84, 231-236 (Pubitemid 14006578)
16. Heatherton T, Kozlowski L, Frecker R, Fagerstrom K (1991). The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. British Journal of Addiction 86, 1119-1127
17. Henningfield J, Stapletom J, Benowitz N, Grayson R, et al. (1993). Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug and Alcohol Dependence 33, 23-29 (Pubitemid 23219906)
18. Innis R, Cunningham V, Delforge J, Fujita M, et al. (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism 27, 1533-1539 (Pubitemid 47301451)
19. Kahlil A, Steyn S, Castagnoli N (2000). Isolation and characterization of monoamine oxidase inhibitor from tobacco leaves. Chemistry Research and Toxicology 13, 31-35 (Pubitemid 30055956)
20. Lunell E, BergströmM, Antoni G, La ngströmB, Nordberg A (1996). Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. Clinical Pharmacology and Therapeutics 59, 593-594 (Pubitemid 26193893)
21. Lunell E, Molander K, Leischow S, Fagerström K (1995). Effect of nicotine vapour inhalation on the relief of tobacco withdrawal symptoms. European Journal of Clinical Pharmacology 48, 235-240
22. Mansvelder H, Keath J, McGehee D (2002). Synaptic mechanisms underlie nicotine induced excitability of brain reward areas. Neuron 33, 905-919 (Pubitemid 34246356)
23. Maskos U, Molles B, Pons S, Besson M, et al. (2005). Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436, 103-107 (Pubitemid 40966193)
24. Meyers D, Neuberger J (2008). Cardiovascular effect of bans on smoking in public places. American Journal of Cardiology 102, 1421-1424
25. Monchuk D, Rousu M, Shogren J, Nonnemaker J, et al. (2007). Decomposing the value of cigarettes using experimental auctions. Nicotine and Tobacco Research 9, 93-99 (Pubitemid 47009048)
26. Mukhin A, Gundisch D, Horti A, Koren A, et al. (2000). 5-Iodo-A-85830, an a4b2 subtype-selective ligand for nicotinic acetylcholine receptors. Molecular Pharmacology 57, 642-649 (Pubitemid 30140897)
27. Nestler E (2005). Is there a common molecular pathway for addiction? Nature Neuroscience. 8, 1445-1449 (Pubitemid 41573654)
28. Pfizer (2002). Nicotrol1 NS and Nicotrol1 Inhaler.
29. Picciotto M, Zoli M, Rimondin R, Lena C, et al. (1998). Acetycholine receptors containing the b2 subunit are involved in the reinforcing properties of nicotine. Nature 391, 173-177 (Pubitemid 28092475)
30. Rice M, Cragg S (2004). Nicotine amplifies reward-related dopamine signals in striatum. Nature Neuroscience 7, 583-584 (Pubitemid 38691894)
31. Roll J, Higgins S, Badger G (1996). An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar. Journal of Applied Behavior Analysis 29, 495-504
32. Rose J, Behm F (2004). Extinguishing the rewarding value of smoke cues: Pharmacological and behavioral treatments. Nicotine and Tobacco Research 6, 523-532 (Pubitemid 38967541)
33. Schneider N, Cortner C, Gould J, Olmstead MKR (2008). Comparison of craving and withdrawal among four combination nicotine treatments. Human Psychopharmacology 23, 513-517
34. Schneider N, Olmstead R, Franzon M, Lunell E (2001). The Nicotine Inhaler: Clinical pharmacokinetics and comparison with other nicotine treatments. Clinical Pharmacokinetics 40, 661-684 (Pubitemid 32954989)
35. Schneider N, Olmstead R, Nilsson F, Mody F, et al. (1996). Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 191, 1293-1306 (Pubitemid 26315887)
36. Schneider N, Terrace S, Koury M, Patel S, et al. (2005). Comparison of three nicotine treatments: initial reactions and preferences with guided use. Psychopharmacology (Berlin) 182, 545-550 (Pubitemid 41464636)
37. Sofuoglu M, Mouratidis M, Yoo S, Kosten KCT (2005). Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berlin) 181, 504-510 (Pubitemid 41480899)
38. Staley J, Dyck Cv, Weinzimmer D, Brenner E, et al. (2005). Iodine-123-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility. Journal of Nuclear Medicine 46, 1466-1472 (Pubitemid 46173258)
39. Staley J, Krishnan-Sarin S, Cosgrove K, Krantzler E, et al. (2006). Human tobacco smokers in early abstinence have higher levels of beta2-nicotinic acetylcholine receptors than nonsmokers. Journal of Neuroscience 26, 8707-8714 (Pubitemid 44319406)
40. Stitzer M, Bigelow G (1985). Contingent reinforcement for reduced breath carbon monoxide levels: target-specific effects on cigarette smoking. Addictive Behavior 10, 345-349 (Pubitemid 16174443)
41. Stitzer M, Rand C, Bigelow G, Mead A (1986). Contingent payment procedures for smoking reduction and cessation. Journal of Applied Behavioral Analysis 19, 197-202
42. Stolerman I, Shoaib M (1991). The neurobiology of tobacco addiction. Trends in Pharmacological Science 12, 467-473
43. Tiffany S, Drobes D (1991). The development and initial validation of a questionnaire on smoking urges. British Journal of Addictions 86, 1467-1476
44. Tønnesen P (2009). Smoking cessation: How compelling is the evidence? A review. Health Policy 91 (Suppl. 1), S15-S25
45. Vaupel D, Mukhin A, Kimes A, Horti A, et al. (1998). In vivo studies with [125I]5-IA 85380, a nicotinic acetylcholine receptor radioligand. NeuroReport 9, 2311-2317 (Pubitemid 28338226)
46. Zhang H, Sulzer D (2004). Frequency-dependent modulation of dopamine release by nicotine. Nature Neuroscience 7, 581-582 (Pubitemid 38691893)
47. Zoghbi S, Tamagnan G, Fujita M, Baldwin R, et al. (2001). Measurement of plasma metabolites of (S)-5-[123I]iodo-3-(2-azetidinylmethoxy) pyridine (5-IA-85380), a nicotinic acetylcholine receptor imaging agent, in non-human primates. Nuclear Medicine and Biology 28, 91-96 (Pubitemid 32155969)
48. Zoli M, Lena C, Picciotto M, Changeux J (1998). Identification of four classes of brain nicotinic receptors using beta2 mutant mice. Journal of Neuroscience 18, 4461-4472 (Pubitemid 28280157)